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Cerebral microdialysis (MD) was introduced as a neurochemical monitoring method in the
early 1990s and is currently widely used for the sampling of low molecular weight mole-
cules, signaling energy crisis, and cellular distress in the neurointensive care (NIC) setting.
There is a growing interest in MD for harvesting of intracerebral protein biomarkers of
secondary injury mechanisms in acute traumatic and neurovascular brain injury in the NIC
community.The initial enthusiasm over the opportunity to sample protein biomarkers with
high molecular weight cut-off MD catheters has dampened somewhat with the emerging
realization of inherent methodological problems including protein–protein interaction, pro-
tein adhesion, and biofouling, causing an unstable in vivo performance (i.e., fluid recovery
and extraction efficiency) of the MD catheter.This review will focus on the results of a mul-
tidisciplinary collaborative effort, within the Uppsala Berzelii Centre for Neurodiagnostics
during the past several years, to study the features of the complex process of high molec-
ular weight cut-off MD for protein biomarkers. This research has led to new methodology
showing robust in vivo performance with optimized fluid recovery and improved extraction
efficiency, allowing for more accurate biomarker monitoring. In combination with evolving
analytical methodology allowing for multiplex biomarker analysis in ultra-small MD samples,
a new opportunity opens up for high-resolution temporal mapping of secondary injury cas-
cades, such as neuroinflammation and other cell injury reactions directly in the injured
human brain. Such data may provide an important basis for improved characterization of
complex injuries, e.g., traumatic and neurovascular brain injury, and help in defining targets
and treatment windows for neuroprotective drug development.
Keywords: microdialysis, catheter performance, acute brain injury, neurointensive care, protein biomarkers,
intracranial pressure, biofouling, inflammation
INTRODUCTION
Cerebral microdialysis (MD) is currently widely used for the sam-
pling of low molecular weight (<200 Da) biomarkers of energy
crisis and cellular distress in the neurointensive care (NIC) set-
ting (1). There is an emerging interest in MD for the sampling
of protein-based biomarkers of secondary injury mechanisms in
NIC patients with acute traumatic and neurovascular brain injury
(2–4). Evolving analytical methodology allowing for multiplex
biomarker analysis in 1–25µL individual samples opens a new
possibility for temporal mapping of complex secondary injury cas-
cades, such as inflammation and cell-specific injury components.
In this context, recent MD studies in NIC patients have presented
temporal patterns of inflammatory biomarkers (5–9). The study
by Helmy et al. on multiple (n= 42) inflammatory biomarkers
also supports the notion that the innate immune system of the
brain is activated early after traumatic brain injury (TBI), mak-
ing MD an attractive focal sampling method for e.g., cytokines,
chemokines, and neurotrophic factors (5, 10), as a complement to
global biomarker analysis in ventricular cerebrospinal fluid (CSF)
(vide infra).
Numerous in vitro studies have revealed that MD protein bio-
marker sampling is more complex than traditional low molecular
weight biomarker sampling, involving protein–protein interac-
tion, protein–surface interaction, and biofouling [for references,
see Ref. (11, 12)]. By using nano liquid chromatography (nanoLC)
in combination with tandem mass spectrometry (MS/MS), we
showed that the proteins adsorbed onto the MD membrane may
be lost to biomarker analysis in the dialysate since they are pre-
vented from crossing the MD membrane (13). In addition, there
is concern that changes in intracranial pressure (ICP), a common
phenomenon in acute brain injury patients, may influence MD
catheter performance in vivo. Thus, Helmy et al. [(5), Figure 2 in
Supplementary Material] found a significant correlation between
ICP and fluid recovery (FR; the percentage of perfusate collected
after passage through the catheter) with crystalloid perfusion
medium in TBI patients that was abolished by the addition of
3% human albumin, suggesting that the colloid osmotic pressure
of the perfusate is important for optimal MD catheter perfor-
mance. These results have inspired research of the mechanisms
and challenges involved with MD protein biomarker sampling.
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As our published in vitro studies in this area show, using large
dextran colloids in the MD perfusate stabilizes the pressures within
the MD system, leading to FR values close to 100%, which is the
target for comparative studies. Also, by dynamically modifying
the surfaces of the membrane and the inner tubing of the MD
catheter by self-assembly of amphiphilic tri-block polymer coating
(Pluronic® F-127), we were able to decrease the protein adsorp-
tion and increase precision in FR, improving extraction efficiency
(EE, a.k.a. relative recovery; i.e., the concentration of an analyte
in the dialyzate divided by the concentration of the same analyte
in the bulk sample) for some proteins in human ventricular CSF
(11). By using nanoLC MS/MS analysis, we showed that protein
adsorption to the MD membrane was reduced by 33% in surface-
modified compared to control catheters (14). Our hypothesis is
that the combination of large dextran colloids in the MD perfusate
and the lowering of protein adsorption to the MD membrane
and tubing will reduce biofouling and improve FR and protein
biomarker EE, thereby increasing the overall robustness of MD
catheter performance.
This hypothesis was recently tested when our refined MD
methodology was validated in a clinically relevant model of acute
brain injury (15). The results supported our hypothesis by show-
ing that MD catheters with surface modification and Dextran 500
(kDa) in the perfusate had a more stable FR close to 100% that
was insensitive to changes in ICP, no significant difference in the
EE of low molecular weight biomarkers, and an improved and
more homogenous EE for protein biomarkers in response to the
intervention compared to naïve catheters (16).
The purpose of this short review is to describe in more detail the
background in vitro work leading up to this refined methodology.
In addition, we discuss the potential of MD for pattern mapping
and monitoring of a large number of protein biomarkers, using
novel multiplex analytical methodology in ultra-small (1–5µL)
MD samples in the NIC setting.
PROTEIN BIOMARKER SAMPLING WITH MICRODIALYSIS – A
COMPLEX TASK
During the last several years, the search for novel protein biomark-
ers of neurodegenerative diseases has escalated. The priority has
been to examine the proteomics of CSF, due to its direct connec-
tion and neurochemical exchange with the brain. CSF is a colorless
body fluid that contains very few cells (0–4 cells/µL), low protein
concentration (0.05–0.8 mg/mL), and a salt concentration similar
to blood (17). However, the analytical challenge lies in the fact
that the CSF contains a large number of proteins spanning over
a concentration range of at least 10 orders of magnitude (18),
requiring appropriate and reliable sampling, sample treatment,
and detection techniques.
Since its introduction in the 1970s (19), MD has become an
established sampling technique routinely used for several decades
(20, 21). MD was introduced as a clinical sampling method for
neurochemical brain monitoring in NIC patients in the 1990s (22).
Being a unique intracerebral sampling tool, MD is currently used
in NIC worldwide, mainly as a clinical research tool but also for
routine chemical brain monitoring in some neurosurgical centers
(1, 23–27). Inherent limitations, including invasiveness, focal sam-
pling (i.e., representativity of MD data), labor intensiveness, and
cost have thus far prevented a general breakthrough for routine
use of MD in NIC.
Microdialysis is a membrane based in vivo sampling tech-
nique where a perfusion fluid is continuously flowing inside a
hollow fiber membrane and thereby extracting the molecules at
the outside environment. The most important parameter in con-
ventional MD is the EE, which describes the overall efficiency of
the sampling (20). However, when using large pore membranes
(MWCO≥100 kDa), it is equally important to also control the FR
to enable stable,diffusion-driven sampling during the entire exper-
iment/monitoring period, and thereby facilitate correct biological
interpretation of the MD data.
The traditional main use of MD has been to collect small
hydrophilic molecules, e.g., glucose, lactate, pyruvate, glutamate,
glycerol, and urea, from different biological matrices (20). With
the introduction of MD membranes with a MWCO of 100 kDa
or more, the focus has shifted toward developing MD methods
for sampling of larger biomolecules, such as peptides (28, 29),
cytokines (2, 12, 30–33), and other proteins (34–38). The studies
together strongly suggest that MD is a promising tool for targeted
analysis, validation, and monitoring of well described biomarkers
in the NIC setting, as a complement to traditional CSF analysis.
When 100 kDa membranes are used for sampling proteins, the
reported EEs range between 1 and 5% at perfusion flow rates
of 0.5–1.0µL/min (36). However, more alarmingly, the EE for
individual biomarkers has shown to vary extensively despite their
similarities in molecular mass (12). The reproducibility and the
repeatability have been reported to be poor (11, 38, 39), indicat-
ing unreliable and non-robust methodology. Li et al. (40) listed
five challenges that must be considered when sampling proteins
with MD. Firstly, proteins are often present in low concentrations
and a highly dynamic concentration range in CSF. Secondly, the
size of the proteins decreases the diffusion velocity. Thirdly, mem-
branes with large pores are more sensitive to different pressures
and perfusion fluid may be lost or gained in an uncontrolled man-
ner. Fourthly, proteins instantly and dynamically adsorb onto the
membrane and tubing of the MD catheter, leading to catheter foul-
ing. Finally, MD generates small sample volumes containing low
concentration of proteins, which could be problematic to analyze
properly. It is important to have maximum control over all five
challenges to facilitate the transfer of a new MD method from
in vitro to in vivo application. By using a representative CSF sam-
ple material, sampling at 37°C, at a controlled ambient pressure,
etc., the goal of mimicking the CSF conditions in vivo in terms of
sample properties, the concentration, and diffusion properties of
the proteins may be achieved.
DESCRIPTION OF IN VITRO MODEL
The aim of an in vitro system is to test a hypothesis in a con-
trolled environment and then to use that knowledge and apply it
on the in vivo model. The more similar one can design the in vitro
system the more accurate an extrapolation will be to the in vivo
system. The least complex in vitro system would be one catheter
in a sample containing one protein dissolved in water, sampled
in room temperature, atmospheric pressure, and with a perfusate
consisting of water. This is a hydrodynamically unstable system
that will give very varying results with respect to FR and EE. The
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FIGURE 1 | Schematic drawing of a pressurized in vitro MD sampling
system is shown. The chamber held four MD catheters and was used to
study the impact of different pressures present in a MD sampling system
on fluid recovery (42). Pressure parameters tested included perfusion flow
rate, colloid osmotic additives in both perfusate and sample, and static
outside pressure. The precision of the system was <0.5 mmHg and
pressures could be set accurately in order to simulate different NIC
conditions [adopted from Ref. (42)].
most complex in vitro set up would be a multi catheter system
placed in a microchamber containing a biological sample. The
sample should be pressurized to 5–50 mmHg and with high level
of accuracy. The MD sampling should be performed in 37°C with
controlled pH.
Parameters such as temperature, ion strength, and pH can easily
be set in in vitro systems. However, when using membranes with
MWCO≥100 kDa, it is also important to be able to control the sta-
tic outside pressure exerted by the sample. This parameter is most
often overlooked since the outside static pressure often remains on
a constant level throughout the experiment. A pressurized in vitro
experiment is also more complex to carry out since it requires addi-
tional instrumentation and equipment. However, since human
ICP may differ between 2 and 15 mmHg in healthy humans (41)
to more than 50 mmHg in NIC patients; such changes may have
a significant impact on the FR and hence the EE. Therefore, we
decided to develop a more complex in vitro model. Figure 1 shows
a schematic drawing of a pressurized in vitro sampling system.
The chamber holds four MD catheters and was used to study the
impact of different pressures present in a MD sampling system on
FR (42). The pressure parameters that were tested included perfu-
sion flow rate, colloid osmotic additives in perfusate, and sample,
as well as static outside pressure. The precision of the system was
<0.5 mmHg, and pressures could be set accurately in order to
simulate different NIC conditions.
FLUID BALANCE AND SENSITIVITY TO CHANGES IN
EXTERNAL PRESSURE
It was found that increased external pressure also increased the FR
(42), which was in agreement with a previous study (43). However,
FIGURE 2 | Fluid recovery plotted as a function of external sample
pressure. In vitro MD test fluid recovery plotted as a function of external
sample pressure in dextran sample (blue) and plasma sample (green) (42).
Reprinted with permission from Chu (42). Copyright 2014 Springer Science
Media.
the increase in FR was also highly dependent on the perfusion
fluid flow rate and the concentration of colloid osmotic agent
in both the perfusate and the sample. The FR increased faster
with decreased perfusion flow rate. For example, FR increased
from 108% (0 mmHg) to approximately 800% (50 mmHg) when
a perfusion flow rate of 0.5µL/min was used in a system with-
out colloid osmotic agents. When the flow rate was increased to
1µL/min, the FR increase was less dramatic, from 72% (0 mmHg)
to approximately 500% (50 mmHg). The in vitro MD system was
very sensitive to pressure changes, but the addition of colloids in
the perfusion fluid resulted in a much more stable in vitro sys-
tem where FR increased from around 90% (0 mmHg) up to 200%
(50 mmHg) when 3% w/v Dextran 500 (kDa) was used in the per-
fusate. Furthermore, the in vitro system was more stable and less
sensitive to external pressure changes when colloids were added in
both the perfusate and in the sample chamber. FR increased from
90% (0 mmHg) to 117% (50 mmHg) when 3% w/v Dextran 500
(kDa) was added to the sample (Figure 2). The findings underline
the importance of controlling the external, hydraulic, and osmotic
pressures during in vitro MD, especially when mimicking MD
sampling applications with elevated pressures, e.g., intracranial
hypertension.
In addition, it is pertinent to control the fluid balance. High
MWCO MD membranes (≥100 kDa) are ultra-filtration mem-
branes and more sensitive to different pressures, meaning that
their fluid characteristics may move from the traditional dialysis
area into ultra-filtration, where fluid flow has to be considered,
and diffusive transport may not always dominate the molecu-
lar transport. It is therefore advantageous to strive for a FR of
100% (i.e., the volume pumped into the MD catheter should also
exit) to secure a diffusion-driven dialysis sampling to provide
time resolved samples that are collected with minimal effect on
the microenvironment. If the FR is smaller than 100%, perfusion
fluid will leak out from the membrane and dilute the microen-
vironment. If the FR is larger than 100%, the opposite effect will
take place, i.e., the flux of water from the sample to the dialyzate
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FIGURE 3 |Temporal evolution of MD catheter dextran leakage pattern is
shown. All images are color coded according to the pixel color-dextran
molecular concentration linearity, to reveal quantitative information on the
dextran leakage. The scale bars on the right show the dextran molar
concentration (millimolar) depending on the pixel color. The pixels, which have
color over the linear zone are all marked as non-linear (“NL”), which is
displayed in dark red. Hundred kilodaltons of MWCO membranes are used
(100 kDa Brain Microdialysis Catheter, M Dialysis AB). For Dextran 40 (kDa),
three image timings are: 0 s, 1 min 14 s, 2 min 18 s; for Dextran 250 (kDa), the
image timings are: 0 s, 1 min 10 s, 6 min 30 s; and for Dextran 500 (kDa), the
image timings are: 0 s, 1 min 11 s, 6 min. Reprinted with permission from Chu
(46). Copyright 2014 Springer Science Media.
through the MD membrane, may result in a higher concentration
of larger molecules at the vicinity of the MD membrane. In the
course of a disease process with dynamic ICP, FR may fluctuate
causing unstable MD catheter performance. One way to stabilize
fluidic flow is to increase the osmotic pressure of the perfusate. This
may be done by adding a colloid such as albumin to the perfusate
(12, 33–35). However, albumin is not compatible with proteomic
applications, which use LC in combination with MS-based detec-
tion since any added albumin would completely dominate the
sample loading in both the LC and the MS signal. As an alterna-
tive to albumin, dextrans with a molecular mass of 60–70 kDa,
have been used to increase the osmotic pressure. (30, 37, 38, 40,
44, 45). Dextrans, which is the collective name for large (1 kDa –
2 MDa) and neutral polysaccharides, can easily be removed prior
to separation and detection and do thereby not affect the MS
signal.
When using membranes with MWCO≥100 kDa, dextrans with
average size of 500 kDa should be used in order to avoid leakage
to the sample (46). In a recent study, an in vitro MD microcham-
ber was manufactured with dimensions of a standard microscope
slide (27 mm× 79 mm) and ability to hold one MD catheter. The
high MWCO catheter (100 kDa Brain Microdialysis Catheter, M
Dialysis AB) was perfused with differently sized fluorescent dex-
trans with the aim to investigate leakage patterns. Leakage patterns,
due to MD phenomena such as bubble formation, cracked mem-
branes, inward ultra-filtration flux, and diffusion, were analyzed
in real time using a fluorescence microscope. A semi-quantitative
analysis was performed on perfusates containing dextrans with
average sizes of 40, 250, and 500 kDa. It was found that both Dex-
tran 40 (kDa) and Dextran 250 (kDa) leaked extensively despite
the 100 kDa MWCO membrane (Figure 3). The explanation may
be that the MWCO of a membrane is equal to the MW at which
80% of the molecules are prevented from flux through the dialysis
membrane (47), meaning that the MWCO is not an absolute mea-
sure of the pore size of the membranes. Another reason may be
that the declared MW of dextran is based on an approximation of
a distribution of MWs in the solution, meaning that dextran mol-
ecules with both considerably larger and lower MWs are present.
For example, a certified, 270 kDa dextran standard has a MW-
dispersion ranging from 13 kDa to 6.4 MDa and around 14% of the
dextrans in a 270 kDa dextran standard are smaller than 100 kDa.
As can be seen in Figure 3, no leakage was observed when Dex-
tran 500 (kDa) was used as perfusate. We therefore recommend
that 100 kDa membrane MD catheter users switch to Dextran 500
(kDa) rather than using Dextran 60 (kDa) in the perfusate.
INTRACRANIAL PRESSURE SENSITIVITY IN VIVO
There is concern that changes in ICP, a common phenomenon in
acute brain injury patients, may influence the in vivo performance
of 100 kDa MWCO catheters widely used in the NIC setting. This
was based on a study by Helmy et al. [(5), Figure 2 in Supplemen-
tary Material] who found a significant correlation between ICP
and FR with crystalloid perfusion medium in TBI patients that
was alleviated by the addition of 3% human albumin, suggesting
that the colloid osmotic pressure of the perfusate is important for
optimal MD catheter performance.
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FIGURE 4 | Relation between fluid recovery and ICP for naïve and
modified MD catheters is shown. The two diagrams show the relation
between FR and ICP for the naïve (upper) and the modified (lower) MD
catheters (100 kDa Brain Microdialysis Catheter, M Dialysis AB), both
perfused (1µL/min) with Perfusion Fluid CNS with in-house addition of 3%
Dextran 500 (kDa). Each circle is the FR of an individual MD vial plotted
against the mean ICP at the end of each corresponding 20-min period. A
linear regression line is plotted with 95% confidence interval. Upper panel
shows a significant positive correlation between FR and ICP in naïve MD
catheters with a high degree of variability (r = 0.30, p=0.02, Standard Error
of Estimate= 32.3). Lower panel shows that this correlation switched to a
weak negative relation in modified catheters with markedly reduced scatter
(r =−0.04, p=0.04, Standard Error of Estimate=4.8), suggesting a more
stable MD performance as a result of surface modification (16). Reprinted
with permission from Dahlin et al. (16). Copyright American Chemical
Society.
In a recent study in a porcine model of acute brain injury
caused by a gradual elevation of ICP leading to brain death (15),
we tested the FR of naïve and adjacent MD catheters (100 kDa
Brain Microdialysis Catheter, M Dialysis AB, Stockholm, Sweden)
surface coated with Pluronic F-127. Both catheters were perfused
(1µL/min) with Perfusion Fluid CNS (M Dialysis) with a 3% in-
house addition of Dextran 500 (kDa) (16). We found a significant
positive correlation between FR and ICP in naïve MD catheters
(Figure 4, upper panel) with a high degree of variability (r = 0.30,
p= 0.02, Standard Error of Estimate= 32.3). However, in surface-
modified catheters (Figure 4, lower panel), the FR dependency
of ICP was virtually abolished with markedly reduced scatter
among data points (r =−0.04, p= 0.04, Standard Error of Esti-
mate= 4.8), suggesting a more stable MD performance as a result
of surface modification in combination with Dextran 500 (kDa).
We believe that this improvement in the FR performance of the
MD catheter in a clinically relevant range of ICP and CPP levels is
instrumental for a stable and diffusion-driven biomarker sampling
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in the NIC setting. Furthermore, the use of Dextran 500 (kDa) in
the perfusate may improve the safety of clinical MD based on the
concern that leakage of Dextran 70 (kDa) from the MD catheter
may cause an inflammatory reaction in the tissue, which may be
prevented by the use of Dextran 500 (kDa) as colloid (8, 48).
It is our working hypothesis that a stable FR close to 100% is
instrumental for a purely diffusion-driven and stable EE as sup-
ported by our in vivo data showing a more homogenous biomarker
response to intracranial hypertension in modified compared to
naïve MD catheters (16). However, EE in modified catheters
improved for some but not for all proteins, suggesting that the
effect of ICP on EE is a complex issue. For example, elevated ICP
may lead to increased protein levels in the interstitial space related
to, e.g., cell damage and BBB leakage, leading to changes in pro-
tein interactions that may influence EE for individual proteins in
a complex fashion. To better understand the precise mechanisms
involved, we are in the process of studying the effect of ICP on EE
in our pressurized in vitro sampling model described above (42).
Such knowledge may provide a basis for further refinement and
optimization of the MD method.
BIOFOULING
As always when a foreign material is inserted into a living organism
or biologically active sample, a response will occur. The forma-
tion of a protein layer due to adsorption is considered to be the
first step in the acute biological response to foreign material (49).
This layer is the foundation for further processes, which eventually
lead to protein fouling, inflammatory reactions, and encapsula-
tion of the membrane (50, 51). The protein adsorption process
is very complex and highly dynamic (52), implying that the pro-
tein composition of the surface layer is constantly changing. This
affects the properties of the MD catheter membrane by chang-
ing the surface chemistry and the membrane pore size (37, 38,
53). Proteins may also be adsorbed to the membrane whereby
they escape detection, a discovery recently presented in a qual-
itative analysis of the protein distribution from a human CSF
sample in an in vitro MD sampling system (13). A total of 134
different proteins were found in the four analyzed sample com-
partments (CSF start, Membrane, Dialyzate, CSF end). Most of
the identified proteins (n= 87) were uniquely found in one sam-
ple compartment only. Abundant CSF proteins such as albumin,
apolipoproteins, and cystatin C together with plasma proteins such
as hemoglobin and fibrinogen were among the 11 proteins that
were found in all samples. The proteins adsorbed onto the mem-
brane were significantly more hydrophobic, had a lower instability
index, and were more thermostable compared to the proteins in
the CSF and the dialyzate (Figure 5). The results suggest that pro-
teins adsorbed onto the MD membranes may escape detection
because they are prevented from passing through the membrane
into the dialysate. It was concluded that the membrane needs to be
examined after sample collection in order to better verify the pro-
tein content in the original sample. This is particularly important
when searching for new protein biomarkers for neurodegenerative
diseases.
FIGURE 5 | Distribution histograms for proteins in CSF, on the MD
membrane, and in the dialyzate are shown. Protein distribution
histograms for protein properties of the proteins identified in CSF (top,
blue), adsorbed to the MD membrane (middle, green) and in the dialyzate
(bottom, red). The 11 proteins found in all samples are excluded. The
proteins are divided in fractions depending on their calculated number of
each property. The investigated properties are (A) molecular weight,
(B) isoelectric point, (C) GRAVY score, (D) instability index, and (E) aliphatic
index. The y -axis is the number of proteins found within the range (x -axis).
The line in each histogram represents the median value, which is also
written next to the line, n=59 for CSF, n=63 for membrane, and n=59 for
dialyzate. The proteins adsorbed onto the membrane had a significantly
lower instability index (i.e., more stable), were more hydrophobic (i.e.,
higher GRAVY score), and were more thermostable (i.e., higher aliphatic
index), compared to the proteins in the CSF and the dialyzate. The results
suggest that proteins may escape detection because they are adsorbed
onto the MD membranes and thereby prevented from passing the
membrane into the dialyzate [(13), Figure S1 in Supplementary Material].
Reprinted with permission from Wetterhall et al. (13). Copyright 2014
Elsevier.
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One way to reduce and delay protein adsorption is to modify
the membrane surface (54). Recently, we presented an alterna-
tive approach to modify MD catheters by dynamically attach a
tri-block copolymer Poloxamer 407, better known as Pluronic
F-127® to the surfaces of the membranes and tubing (11, 14,
16, 53). Pluronic F-127® is a tri-block copolymer consisting
two hydrophilic polyethyleneoxid (PEO) chains that sandwich a
hydrophobic polypropylenoxide (PPO) unit resulting in a mole-
cular structure PEO98–PPO67–PEO98. In aqueous environment,
the hydrophobic PPO-chain is adsorbed to the polymeric and
hydrophobic catheter material and the hydrophilic PEO-chains
self-assemble into a cilia-like surface that protrude from the
hydrophobic membrane and tubing and effectively hinders pro-
teins to reach the surface (55). According to the Food and Drug
administration (FDA) guide, Pluronic F-127® is regarded to be
an inactive ingredient for different types of preparations such as
inhalations, oral solutions, suspensions, ophthalmic, and topical
formulations (53). In addition, Pluronic F-127®can be sterilized
by autoclaving (120°C, 15 min, 1 bar), which potentially facilitates
unimpeded transition from in vitro to in vivo application.
We found that Pluronic F-127® modified MD catheter mem-
branes adsorbed 33% less proteins than untreated MD membranes
(14). Surface modification also promoted the EE for some proteins
both in vitro (11) and in vivo (16). Another major advantage with
surface-modified MD catheters was a significantly improved FR
precision for both in vivo (Figure 4) and in vitro (Figure 6) MD.
The direct result of improved FR precision was more reliable sam-
pling of protein biomarkers (Figure 7),while low molecular weight
biomarkers were less affected (16).
PROTEIN BIOMARKER ANALYSIS WITH HIGH SENSITIVITY
AND PRECISION – A CHALLENGE
MASS SPECTROMETRY BASED ANALYSIS OF MICRODIALYSATE
PROTEIN BIOMARKERS
The combination of low concentrated protein samples and limited
sample volumes that MD sampling generates require subsequent
separation and the detection method to be both sensitive and selec-
tive. Liquid chromatography (LC) in combination with tandem
mass spectrometry (MS/MS) is universal, selective, and sensitive.
LC-MS is therefore a good choice for the analysis of MD samples.
There are several strategies for quantitative MS proteomics (56,
57). One approach for relative quantification is the isobaric tag
for relative and absolute quantification (iTRAQ®), which enables
multiplexed quantitative analysis of up to eight samples simultane-
ously (58). The benefits of using iTRAQ® for MD sample analysis
are the possibility to perform differential quantification of com-
plex samples under similar conditions. iTRAQ thereby facilitates
direct comparison between the original sample and the dialysate,
which is used to determine the EEs for multiple proteins with high
sensitivity.
The iTRAQ-MS/MS have been applied to both in vitro (11) and
in vivo (16) MD samples. In the in vitro study, 48 proteins were
identified and quantified in the dialysate obtained from sampling
ventricular CSF during 24 h. Six of the most abundant proteins,
with respect to their MASCOT score, were selected for further and
more detailed analysis. Albumin, Transferrin, Clusterin, Comple-
ment C3, Hemopexin, and Hemoglobin Beta were chosen. The EE
for Albumin was on average 17.5± 2.4% for the surface treated
catheters (n= 5) and 17.3± 2.4% for the naïve catheters (n= 5).
FIGURE 6 | Fluid recovery as a function of time for naïve and the
modified MD catheters in vitro. Fluid recovery as a function of fraction
order in in vitro microdialysis in human ventricular CSF. Perfusion fluid
CNS with 3% w/v Dextran 60 was delivered at 0.3µL/min at 37°C. Blue
solid line symbolizes naïve MD catheters and green dotted line
surface-modified (Pluronic F-127) MD catheters (100 kDa Brain
Microdialysis Catheter, M Dialysis AB). Error bars are based on ±1 SD of
four surface-modified and untreated catheters, respectively (11).
Reprinted with permission from Dahlin et al. (11). Copyright American
Chemical Society.
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FIGURE 7 | Protein response to ICP intervention for naïve and modified
MD catheters. Vector diagram showing the response of the 17 most
abundant proteins, according to the Mascot score (i.e., the probability that the
experimental data set matches the database data) quantified in ≥4 animals,
during step-wise intracranial hypertension. Proteins with vectors are relatively
quantified. Proteins tagged with “Id” are identified but not quantified, i.e.,
fulfilling the identification criteria only. Proteins are presented with names,
their Uniprot database number (www.uniprot.org), and their response to
intervention for surface-modified and naïve catheters. The relative protein
amount after intervention (Protein fraction 2, MD fractions 7–12) is compared
with the relative protein amount from before intervention (Protein fraction 1,
MD fractions 1–6). An arrow pointing straight up (↑) means that the particular
protein has increased significantly in concentration by >50% due to the
intervention. An arrow pointing straight down (↓) means that the
concentration of the protein has decreased significantly by >50% in response
to the intervention. Vectors pointing diagonally display either an increase (light
green) or a decrease (orange) of 25–50%. These changes are not statistically
significant but they show interesting tendencies. Finally, vectors pointing to
the right (yellow) range between 0.75 and 1.25 and show no significant
difference between the two fractions. U-protein means uncharacterized
proteins.White boxes means that the protein was not identified or quantified
in the sample. Thus, a white box is a reflection of the sample composition, not
related to MD catheter performance (16). Reprinted with permission from
Dahlin et al. (16). Copyright American Chemical Society.
Albumin showed no significant difference in EE between surface-
modified catheter and naïve catheter. Clusterin and Complement
C3 showed no statistically significant difference in EE between
Pluronic F-127 coated and naïve catheters. Hemopexin, Trans-
ferrin, and Hemoglobin Beta increased significantly in EE when
comparing surface coated to naïve catheters (11).
In the in vivo study (16), 66 proteins were relatively quanti-
fied in one or more animals. However, only proteins that were
quantified in ≥4 animals were considered for further evalua-
tion (n= 17). These 17 proteins, presented in Figure 7, were
used to study the EE performance of the MD catheters. Data
were normalized, and thereafter, proteins in MD samples from
surface-modified versus naïve MD catheters were analyzed by
vector diagrams to illustrate the protein pattern changes in
response to the intervention. The vector diagram analysis showed
a significantly more homogenous protein pattern in response to
the intervention in modified compared to naïve MD catheters.
Three naïve catheters (animals 1, 5, and 6) failed to deliver
stable FR and also showed large variation in protein response.
However, failing catheters was not the only reason for high
variability in protein response, which is apparent in animal 7
(Figure 7). The distinctive behaviors of the modified catheters
were dual: firstly, they promoted the sampling recovery for most
of the proteins found in the dialyzate. Secondly, they presented
a more consistent performance. Both features are advantageous,
if more consistent sampling performance and higher protein
recovery are considered as goals for improving MD in vivo
performance.
The proteins detected in the proteomic analysis of the MD
samples (Figure 7) were used as biomarker models to study the
in vivo performance of naïve compared to membrane modified
MD catheters. However, some of the proteins have functional
properties of relevance to brain injury and might even have some
potential as future biomarkers (Table 1).
ANTIBODY-BASED ANALYSIS OF MICRODIALYSATE PROTEIN
BIOMARKERS
There are a number of publications where the temporal response
of one to several biomarkers of, e.g., inflammation has been stud-
ied in patients with acute brain injury using MD and ELISA-based
analyses (2,3,5–9). These pioneering studies have begun to unravel
the complex features of the inflammatory cascade in acute human
brain injury. The limitations are the rather large sample volumes
required, resulting in poor temporal resolution, as well as a low
number of biomarkers that can be measured in the same sample.
MULTIPLEX MICRODIALYSATE PROTEIN BIOMARKER ANALYSIS
The Luminex technology opens up for new possibilities to mon-
itor complex secondary injury cascades, such as inflammation,
directly in the injured human brain by analyzing a larger number
of biomarkers in relatively small MD samples. Intriguing stud-
ies by Helmy et al. (5, 10) on multiple inflammatory protein
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Table 1 | Functional properties of relevance for a potential future biomarker role for some of the proteins used to study MD catheter in vivo
performance in our porcine brain injury model (16).
Protein MW Function Potential biomarker role
Serum albumin 69.7 Osmotic pressure of blood Breakdown of the blood-brain-barrier
Hemoglobin subunit beta 16.2 Oxygen metabolism Red blood cell degradation product
Serotransferrin 78.9 Iron transport Iron ions in the brain parenchyma
Hemoglobin subunit alpha 15.2 Oxygen metabolism Red blood cell degradation product
Creatine kinase B-type 20.7 Energy metabolism Used to increase accuracy of S100B as a biomarker
Cystatin C 15.7 Inhibits lysosomal proteinases Increased autophagal activity
Apolipoprotein A-1 9.18 Lipid transport Trauma induced membrane remodeling
Alpha-2-HS-glycoprotein (Fetuin-A) 38.4 Ion transport Possible systemic response to brain injury
Apolipoprotein E 36.7 Lipid transport Trauma induced membrane remodeling
Complement C3 184 Innate immunity Innate immune response to brain injury
MW, molecular weight (kDa); protein function; potential role as a biomarker of acute brain injury. For Uniprot data, see Figure 7. For further discussion, see Ref. (16).
biomarkers (measured in duplicate 25µL samples using a Mil-
liplex MultiAnalyte 42 analyte kit; Millipore, St Charles, MI, USA)
further demonstrated the complexity of the temporal inflamma-
tory biomarker patterns in NIC patients with severe diffuse TBI.
It was also demonstrated that about half of the 42 biomarkers
appeared in higher concentration in MD samples than in arterial
plasma suggesting intracerebral biomarker production (5). The
data support the concept that the innate immune system of the
brain is activated early after TBI, previously developed based on
clinical and experimental studies showing, e.g., higher cytokine
levels in human CSF compared to blood (59). This makes MD
an attractive focal sampling method for many biomarkers, such
as cytokines, chemokines, and neurotrophic factors, as a comple-
ment to traditional global biomarker analysis in ventricular CSF.
The advantage of MD sampling is that it catches the inflamma-
tory mediators in the interstitial space at the site of their cellular
actions, also avoiding dilution of the biomarker signals in CSF. In
addition, the MD work (5, 10) strongly supports the potential of
multiplex analytical methodology as tools to study complex sec-
ondary injury cascades directly in the human brain. However, a
limitation is the time resolution, which is currently 6 h with the
standard MD set up widely used in the NIC setting.
Proximity ligation technology
To improve analytical sensitivity and precision, we are collabo-
rating with the Uppsala Berzelii Technology Centre for Neuro-
diagnostics (www.berzelii.uu.se) to use proximity ligation assay
(PLA) technology (60) to apply multiplex panels of biomark-
ers of brain injury and inflammation in MD samples from TBI
patients. Because of the superior sensitivity of the PLA technology
compared to conventional sandwich assays (61), we assume that
this methodology will have a significantly better time resolution.
Another advantage with the Berzelii Centre collaboration is that
the PLA multiplex panels can be continuously modified locally as
our knowledge of clinically useful biomarkers evolves. Preliminary
results support the feasibility of this approach. Pilot data show
that modern multiplex PLA panels, based on the new generation
Proximity Extension Assay (PEA) technology (Olink Bioscience,
Uppsala, Sweden) can measure about 80 biomarkers, including
inflammatory mediators, in very small (1µL) MD samples from
TBI patients (unpublished data not shown). This emerging tech-
nology may become a powerful tool for biomarker discovery
with the potential of analyzing 400–500 biomarkers in hourly
MD samples (and in CSF samples) allowing for temporal map-
ping of individual biomarker profiles as well as complex temporal
biomarker patterns.
FUTURE PERSPECTIVES
Our working hypothesis is that the combination of the refined
MD method and the new generation PEA panels of multiplex bio-
marker panels will provide a unique possibility for future studies
of the secondary injury cascades following acute human brain
injury, paving the way to a better understanding of the complex
pathobiology involved and the identification of novel biomarkers
and targets for therapeutic intervention. Finally, dedicated smaller
bed side PEA panels including the most valuable biomarkers may
prove to be useful for individual patient monitoring and tailored
treatment in the future NIC setting.
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